Search

Your search keyword '"Tomassini JE"' showing total 34 results

Search Constraints

Start Over You searched for: Author "Tomassini JE" Remove constraint Author: "Tomassini JE" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
34 results on '"Tomassini JE"'

Search Results

1. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US

2. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy

Catalog

Books, media, physical & digital resources

3. Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.

4. Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.

5. Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.

7. Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.

8. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus.

9. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.

10. Statin combination therapy and cardiovascular risk reduction.

11. Time-related trends in variability of cIMT changes in statin trials.

12. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.

13. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.

14. Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.

15. Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis.

16. Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial.

17. Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.

18. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.

19. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.

20. Inhibitory effect of 2'-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells.

21. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties.

22. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro.

23. An in vitro Flaviviridae replicase system capable of authentic RNA replication.

24. Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs.

25. Synthesis of natural flutimide and analogous fully substituted pyrazine-2,6-diones, endonuclease inhibitors of influenza virus.

26. A novel antiviral agent which inhibits the endonuclease of influenza viruses.

27. Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors.

28. Antibodies that block rhinovirus attachment map to domain 1 of the major group receptor.

29. Bacterial expression of antibody fragments that block human rhinovirus infection of cultured cells.

30. Neutralizing monoclonal antibodies to hepatitis A virus: partial localization of a neutralizing antigenic site.

31. Biochemical characterization of a glycoprotein required for rhinovirus attachment.

32. Isolation of a receptor protein involved in attachment of human rhinoviruses.

33. Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments.

34. cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1.